Abbisko’s New Cancer Drug Enters Clinical Trial

Abbisko Cayman Limited (HK:2256) has released an update.

Abbisko Cayman Limited’s subsidiary, Abbisko Therapeutics, in collaboration with Shanghai Allist Pharmaceuticals, has secured approval from China’s National Medical Products Administration (NMPA) for the phase I clinical trial of ABK3376, a promising new EGFR inhibitor targeting non-small cell lung cancer with specific resistance mutations. The drug, which has shown potential in preclinical studies for both safety and effectiveness, could offer a new targeted therapy option for patients with this form of lung cancer. Investors are advised to exercise caution as the company cannot guarantee the drug’s successful market introduction.

For further insights into HK:2256 stock, check out TipRanks’ Stock Analysis page.